ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin
Richard J. Anderson(University of Maryland, Baltimore), Fernando Noriega(Novavax (United States)), Marcelo B. Sztein(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore), Marcela F. Pasetti(University of Maryland Global Campus)
Cited by 49
Related Papers
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
|New England Journal of Medicine|2014|941
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372